
    
      The purpose phase I of this trial is to characterize safety and tolerability and determine
      the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of MAK683.

      The purpose of the phase II of this trial will be to evaluate the anti-tumor activity of
      MAK683.
    
  